Insider Buying: Immuneering Co. (NASDAQ:IMRX) Director Acquires $63,750.00 in Stock

Immuneering Co. (NASDAQ:IMRX) Director Peter Feinberg acquired 25,000 shares of Immuneering stock in a transaction on Friday, March 22nd. The stock was purchased at an average price of $2.55 per share, with a total value of $63,750.00. Following the transaction, the director now directly owns 111,766 shares in the company, valued at approximately $285,003.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Immuneering Stock Performance

NASDAQ:IMRX opened at $2.43 on Thursday. Immuneering Co. has a 12 month low of $1.90 and a 12 month high of $14.29. The company’s 50-day moving average price is $5.48 and its two-hundred day moving average price is $6.36.

Immuneering (NASDAQ:IMRX) last announced its earnings results on Friday, March 1st. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.06). As a group, analysts forecast that Immuneering Co. will post -1.89 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of IMRX. Tower Research Capital LLC TRC boosted its position in Immuneering by 296.1% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,248 shares of the company’s stock valued at $25,000 after buying an additional 2,428 shares during the last quarter. UBS Group AG acquired a new position in shares of Immuneering during the first quarter valued at $26,000. California State Teachers Retirement System boosted its holdings in Immuneering by 81.8% in the first quarter. California State Teachers Retirement System now owns 8,124 shares of the company’s stock valued at $53,000 after acquiring an additional 3,656 shares during the last quarter. Occudo Quantitative Strategies LP acquired a new stake in Immuneering in the second quarter worth about $57,000. Finally, American International Group Inc. raised its holdings in Immuneering by 111.1% during the 1st quarter. American International Group Inc. now owns 9,432 shares of the company’s stock worth $61,000 after purchasing an additional 4,964 shares during the last quarter. Institutional investors own 67.65% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on IMRX shares. Guggenheim restated a “neutral” rating on shares of Immuneering in a research note on Thursday, March 14th. Oppenheimer reaffirmed an “outperform” rating and set a $25.00 price objective on shares of Immuneering in a report on Tuesday, March 5th. Chardan Capital lowered their target price on shares of Immuneering from $21.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday, March 15th. Needham & Company LLC cut their price target on shares of Immuneering from $20.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, March 15th. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $3.00 price objective (down from $16.00) on shares of Immuneering in a research note on Friday, March 15th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Immuneering presently has an average rating of “Moderate Buy” and an average price target of $15.50.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.